Protalix BioTherapeutics (PLX) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $48.7M
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.69 -0.37%
Revenue Growth %: -33.6%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -33.6%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.09), $0.09 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.05 million versus the consensus estimate of $6.9 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Can global equities keep rising? UBS sees these factors driving upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
